94 Consolidated income statement for the year ended 31st December 2009 2009 Results before major Major restructuring restructuring Total Notes m m m Turnover 6 28,368 28,368 Cost of sales 7,095 285 7,380 Gross profit 21,273 285 20,988 Selling, general and administration 9,200 392 9,592 Research and development 3,951 155 4,106 Other operating income 8 1,135 1,135 Operating profit 9,10 9,257 832 8,425 Finance income 11 70 70 Finance costs 12 780 3 783 Profit on disposal of interest in associate 115 115 Share of after tax profits of associates and joint ventures 13 64 64 Profit before taxation 8,726 835 7,891 Taxation 14 2,443 221 2,222 Profit after taxation for the year 6,283 614 5,669 Profit attributable to minority interests 138 138 Profit attributable to shareholders 6,145 614 5,531 6,283 614 5,669 Basic earnings per share pence 15 109.1p Diluted earnings per share pence 15 108.2p The calculation of Results before major restructuring is described in Note 1, Presentation of the financial statements.
Consolidated statement of comprehensive income for the year ended 31st December 2009 2009 2008 2007 m m m Profit for the year 5,669 4,712 5,310 Exchange movements on overseas net assets and net investment hedges 194 1,017 411 Reclassification of exchange on liquidation of overseas subsidiary 44 84 Tax on exchange movements 19 15 21 Fair value movements on available-for-sale investments 42 47 53 Deferred tax on fair value movements on available-for-sale investments 24 5 8 Reclassification of fair value movements on available-for-sale investments 34 46 Deferred tax reversed on reclassification of available-for-sale investments 13 3 11 Actuarial losses gains on defined benefit plans 659 1,370 671 Deferred tax on actuarial movements in defined benefit plans 183 441 195 Fair value movements on cash flow hedges 6 6 6 Deferred tax on fair value movements on cash flow hedges 2 3 2 Reclassification of cash flow hedges to income and expense 1 Fair value movement on subsidiary acquisition 6 Other comprehensive expense income for the year 673 117 824 Total comprehensive income for the year 4,996 4,829 6,134 Total comprehensive income for the year attributable to: Shareholders 4,895 4,670 6,012 Minority interests 101 159 122 Total comprehensive income for the year 4,996 4,829 6,134 GSK Annual Report 2009 Financial statements P91P182 Business review P06P53 Governance and remuneration P54P90 Financial statements P91P182 Shareholder information P183P204 95 2009 2008 2007 Results Results Results before major Major before major Major before major Major restructuring restructuring Total restructuring restructuring Total restructuring restructuring Total Notes m m m m m m m m m Turnover 6 28,368 28,368 24,352 24,352 22,716 22,716 Cost of sales 7,095 285 7,380 5,776 639 6,415 5,206 111 5,317 Gross profit 21,273 285 20,988 18,576 639 17,937 17,510 111 17,399 Selling, general and administration 9,200 392 9,592 7,352 304 7,656 6,817 137 6,954 Research and development 3,951 155 4,106 3,506 175 3,681 3,237 90 3,327 Other operating income 8 1,135 1,135 541 541 475 475 Operating profit 9,10 9,257 832 8,425 8,259 1,118 7,141 7,931 338 7,593 Finance income 11 70 70 313 313 262 262 Finance costs 12 780 3 783 838 5 843 453 453 Profit on disposal of interest in associate 115 115 Share of after tax profits of associates and joint ventures 13 64 64 48 48 50 50 Profit before taxation 8,726 835 7,891 7,782 1,123 6,659 7,790 338 7,452 Taxation 14 2,443 221 2,222 2,231 284 1,947 2,219 77 2,142 Profit after taxation for the year 6,283 614 5,669 5,551 839 4,712 5,571 261 5,310 Profit attributable to minority interests 138 138 110 110 96 96 Profit attributable to shareholders 6,145 614 5,531 5,441 839 4,602 5,475 261 5,214 6,283 614 5,669 5,551 839 4,712 5,571 261 5,310 Basic earnings per share pence 15 109.1p 88.6p 94.4p Diluted earnings per share pence 15 108.2p 88.1p 93.7p The calculation of Results before major restructuring is described in Note 1, Presentation of the financial statements.
Consolidated statement of comprehensive income for the year ended 31st December 2009 2009 2008 2007 m m m Profit for the year 5,669 4,712 5,310 Exchange movements on overseas net assets and net investment hedges 194 1,017 411 Reclassification of exchange on liquidation of overseas subsidiary 44 84 Tax on exchange movements 19 15 21 Fair value movements on available-for-sale investments 42 47 53 Deferred tax on fair value movements on available-for-sale investments 24 5 8 Reclassification of fair value movements on available-for-sale investments 34 46 Deferred tax reversed on reclassification of available-for-sale investments 13 3 11 Actuarial losses gains on defined benefit plans 659 1,370 671 Deferred tax on actuarial movements in defined benefit plans 183 441 195 Fair value movements on cash flow hedges 6 6 6 Deferred tax on fair value movements on cash flow hedges 2 3 2 Reclassification of cash flow hedges to income and expense 1 Fair value movement on subsidiary acquisition 6 Other comprehensive expense income for the year 673 117 824 Total comprehensive income for the year 4,996 4,829 6,134 Total comprehensive income for the year attributable to: Shareholders 4,895 4,670 6,012 Minority interests 101 159 122 Total comprehensive income for the year 4,996 4,829 6,134 GSK Annual Report 2009
